Home > Journals > Acta Phlebologica > Past Issues > Acta Phlebologica 2001 Apri;2(1) > Acta Phlebologica 2001 April;2(1):43-9

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

ACTA PHLEBOLOGICA

A Journal on Phlebology


Official Journal of the Italian College of Phlebology
Indexed/Abstracted in: EMBASE, Scopus, Emerging Sources Citation Index


eTOC

 

TECHNICAL NOTES  


Acta Phlebologica 2001 April;2(1):43-9

language: English, Italian

Postsclerotherapy occur­rance of hyper­pig­men­ta­tion and oth­er ­local and system­i­cal ­signs in the treat­ment of ­small ves­sels varic­es ­with dif­fer­ent scle­roth­e­rap­ic ­agents. Preliminary ­report

Santoro P. 1, Blandamura M. 1, Chiti D. 2, Scaramuzzino L. 3

1 Clinica Angiomedica - Roma;
2 Ambulatorio Angiologico - Prato (Firenze);
3 Università ­degli Studi - Catanzaro, Scuola di Specializzazione in Chirurgia Vascolare, AO NA1 Ospedale Loreto Mare


PDF  


BACKGROUND: To determine the safe­ty of a ­short ­term use of pur­i­fied sodi­um tet­ra­dec­yl sul­phate in ­form of ­water solu­tion or ­foam ­obtained accord­ing to Tessari’s meth­od in the treat­ment of ­small ves­sels varic­es.
METHODS: One hun­dred and two ­patients of ­which 18 ­male and 84 ­female of ­about 38 mid­dle age ­were treat­ed for 3 ­months ­with 3 dif­fer­ent scler­o­sant ­agents pur­i­fied sodi­um tet­ra­dec­yl sul­phate, chro­mat­ed gly­ce­rin, phol­i­doc­a­nol in telan­giec­tas­es and retic­u­lar ­veins. Each ­patient ­received 8 scle­roth­e­rap­ic treat­ments and the 3 scler­o­sant ­agents ­were ­used in ­form of ­water solu­tion or ­foam begin­ning ­from ­known con­cen­tra­tions and dilut­ed at ­desired con­cen­tra­tions ­using a ­water 2% solu­tion of car­bo­caine or phys­io­log­ic solu­tion.
RESULTS: In all the ­patients treat­ed ­with the ­three dif­fer­ent scler­o­sant ­agents, ­there ­were not iso­lat­ed ­signs of escha­ra; ­there ­were 2 cas­es of ear­ly hyper­pig­men­ta­tions (2% of the cas­es treat­ed) ­with the use of pur­i­fied sodi­um tet­ra­dec­yl sul­phate, 4 cas­es (3.9% of the cas­es treat­ed) ­with the use of chro­mat­ed gly­ce­rin and 5 cas­es (4.9%) ­with the use of phol­i­doc­a­nol; ­there ­were iso­lat­ed 2 cas­es (2%) of ­local ­signs of aller­gy ­with the use of pur­i­fied sodi­um tet­ra­dec­yl sul­phate, 6 cas­es (5.9%) ­with the use of chro­mat­ed gly­ce­rin and 8 cas­es (6.8%) ­with the use of phol­i­doc­a­nol; the ­patient’s com­pli­ance was ­good in 97 cas­es (95.1%) ­with the use of pur­i­fied sodi­um tet­ra­dec­yl sul­phate and ­good in 92 cas­es (90.2%) ­with the use of ­both chro­mat­ed gly­ce­rin and phol­i­doc­a­nol. Finally, cas­es of hyper­sen­si­tiv­ity and system­i­cal­ly aller­gy ­signs (anaph­y­lax­is) asso­ciat­ed ­with the use of ­these ­three dif­fer­ent scler­o­sants ­were not ­observed.
CONCLUSIONS: Sodium pur­i­fied tet­ra­dec­yl sul­phate has ­shown to be a scler­o­sant ­agent ­with a ­high safe­ty ­index in the treat­ment of ­small ves­sels varic­es ­both in ­water solu­tion or ­foam, espe­cial­ly for the inci­dence of cuta­ne­ous ­signs of esthet­i­cal inter­est (ear­ly hyper­pig­men­ta­tion and telan­giec­tat­ic mat­ting, ­local aller­gic ­signs) and for the ­patient’s com­pli­ance com­pared ­with the ­most ­employed and ­safe scler­o­sant ­agents actu­al­ly avail­able in ther­a­py. The use of ­foam can ­also high­ly ­reduce the con­cen­tra­tion and the vol­ume of the scle­ros­ing ­drug to use, so ­that the inci­dence of ­local ­signs of inflam­ma­tion, ­eschar, ­pain ­after treat­ment and hyp­er pig­men­ta­tions is low­er.

top of page

Publication History

Cite this article as

Corresponding author e-mail